CLDND2: A Potential Drug Target and Biomarker (G125875)

Target Name: CLDND2

NCBI ID: G125875

CLDND2

Other Name(s): Claudin domain-containing protein 2 | CLDN2_HUMAN | claudin domain containing 2 | Claudin domain containing 2

CLDND2: A Potential Drug Target and Biomarker

CLDND2, or Claudin domain-containing protein 2, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique protein structure and various functions make it an intriguing candidate for further research and development as a drug.

The Claudin family of proteins plays a crucial role in cell signaling and signaling pathways. The 26 member family consists of five subfamilies, each characterized by a unique N-terminus and a C-terminus. CLDND2 belongs to the CLDND subfamily, which is characterized by the presence of a specific domain called the Claudin domain.

The Claudin domain is a unique structural feature that consists of a series of amino acids that form a 尾-helix. This 尾-helix is 鈥嬧?媟esponsible for the protein's stability and functions as a scaffold, which can interact with other proteins and molecules. CLDND2 has a unique 尾-helix structure that is specific to this protein and allows it to interact with various ligands, including small molecules, ions, and proteins.

CLDND2's unique structure also makes it a potential drug target. The 尾-helix is 鈥嬧?媋 structural feature that can be targeted by small molecules, which can alter the protein's stability and function. This can lead to changes in the protein's activity and contribute to the development of various diseases.

In addition to its potential as a drug target, CLDND2 has also been identified as a potential biomarker for various diseases. The CLDND2 gene has been shown to be expressed in various tissues and organs, including brain, heart, liver, and muscle. Additionally, studies have shown that high levels of CLDND2 expression are associated with the development of certain diseases, including neurodegenerative diseases and cancer.

Furthermore, CLDND2 has also been shown to play a role in cellular signaling pathways. Studies have shown that CLDND2 interacts with various proteins, including neurotransmitter receptors, which can influence the transmission of signals within the cell. This interaction between CLDND2 and neurotransmitter receptors suggests that CLDND2 may be a useful biomarker for neurodegenerative diseases, where the disruption of cellular signaling pathways is a common feature.

In conclusion, CLDND2 is a protein that has potential as a drug target and biomarker for various diseases. Its unique protein structure and various functions make it an intriguing candidate for further research and development. As research continues to advance, CLDND2's potential as a drug and biomarker will be further evaluated, and its role in the development of various diseases will be revealed.

Protein Name: Claudin Domain Containing 2

The "CLDND2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDND2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets